BRIEF-AMAG Pharmaceuticals says positive topline data from Feraheme label expansion study
May 2 AMAG Pharmaceuticals Inc
* Announces positive topline data from phase 3 feraheme® (ferumoxytol) label expansion study
* Achieved all primary and secondary safety and efficacy endpoints
* On track to file SNDA mid-year with a potential approval and launch in first half of 2018
* Expects to file a supplemental nda with u.s. Fda by mid-2017 to potentially broaden use of feraheme Source text for Eikon: Further company coverage: (Bangalore.newsroom@thomsonreuters.com)